Test Price
2,800 AED✅ Home Collection Available
DNMT3A Somatic Mutation Analysis for Acute Myeloid Leukemia (NGS) in UAE
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified NGS Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM.
- Clinical Guidance: Telephonic Post-Test Clinical Interpretation by a DHA-Licensed Specialist.
- Insurance: Direct Billing Verification via WhatsApp: +971 54 548 8731.
- Price: 2,800 AED (Comprehensive NGS Analysis).
Test Overview & Methodology
This next-generation sequencing (NGS) test detects DNMT3A gene somatic mutations associated with acute myeloid leukemia (AML). Accurate detection of these mutations aids in risk stratification, prognostic assessment, and therapeutic decision-making for patients with AML. Unlike traditional single-gene methods, NGS provides comprehensive coverage of the entire coding region, identifying both known and novel variants.
| Feature | Our Test (DNMT3A NGS) | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Method | Next-Generation Sequencing (NGS) | Single-Gene Sanger Sequencing |
| Diagnostic Precision | 99.9% sensitivity; detects all coding mutations | ~95% sensitivity; limited to known hotspots |
| Turnaround Time | 3–4 Weeks (Comprehensive) | 2–3 Weeks (Requires follow-up NGS if negative) |
| Variant Detection Scope | All coding exons & intronic boundaries | Only predefined hotspot codons |
Physician Insight & Safety Protocols
“As a Specialist in Diagnostic Radiology, I emphasize that a DNMT3A mutation result provides a powerful prognostic layer in the full AML work-up. It must always be interpreted alongside blast count, cytogenetics, and FLT3/NPM1 mutational status. This test informs targeted therapy and clinical trial eligibility but does not replace a comprehensive clinical evaluation. We strongly recommend a genetic counseling session before sampling to fully understand the implications for disease monitoring and family members.”
— Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology, DHA License: 61713011
Advisory Safety Protocols & Medication Guidance
⚠ Critical Medication Advisory
Do not discontinue prescribed chemotherapy, targeted therapy (e.g., midostaurin, gilteritinib), or hypomethylating agents (e.g., azacitidine) without consulting your treating oncologist. Test results inform future therapy adjustments, but sudden changes can destabilize hematologic status and lead to adverse outcomes.
Patient Exclusion Criteria & Clinical Red Flags
- Exclusion: Active uncontrolled infection (CRP >100 mg/L), severe thrombocytopenia (<10×10⁹/L) requiring immediate platelet transfusion, or anticipated sample hemolysis (risk of DNA degradation).
- Red Flags requiring immediate ER visit: New onset fever >38.3 °C, spontaneous bleeding or bruising, or acute vision changes (possible leukostasis).
- All procedures strictly follow ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139) safety protocols for home phlebotomy and sample integrity.
Patient FAQ & Clinical Guidance
1. What does a positive DNMT3A mutation mean for my AML treatment?
Answer: A positive finding indicates that your acute myeloid leukemia cells carry a DNMT3A alteration. This often correlates with intermediate-risk cytogenetics and may influence eligibility for targeted therapies or clinical trials. Your oncologist will integrate this result with other markers to tailor your treatment plan.
2. Can this test be performed if I have recently received a blood transfusion?
Answer: Transfusion within the last 7 days may dilute circulating leukemic cells. Please inform our phlebotomist or care coordinator so that we can schedule the draw at the optimal time to ensure accurate somatic mutation detection.
3. Will my insurance cover the 2,800 AED cost?
Answer: Most UAE private insurers cover molecular AML testing when pre-authorized. We provide direct billing verification via WhatsApp at +971 54 548 8731 before sample collection to confirm your coverage.
4. How is the sample collected and what logistics are involved?
Answer: A certified phlebotomist will collect a peripheral whole blood sample during a scheduled home visit. The sample is transported via a temperature-controlled cold-chain courier directly to our ISO-certified laboratory. VIP Mobile Phlebotomy is available daily from 8 AM to 11 PM.
UAE Regulatory & Data Privacy Adherence
Data Privacy & Security: Your genetic data is processed under Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent protocols strictly adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability.
Accreditation: ISO 9001:2015 Certified (Certificate INT/EGQ/2509DA/3139). Full compliance with Dubai Health Authority (DHA) licensing standards for genetic and molecular diagnostics.
DHA Facility License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE.
Clinical & Logistical Metadata
| Test Name | DNMT3A Somatic Mutation Analysis (NGS) – Acute Myeloid Leukemia |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood, Bone Marrow Aspirate |
| Methodology Used | Next-Generation Sequencing (NGS) – Illumina Platform |
| ICD-10-CM Code | C92.00 |
| LOINC Code | 91798-3 |
| DHA Facility License & Address | DHA License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians